Dual Immunotherapy Combination Significantly Extends Survival in Advanced Cutaneous Squamous Cell Carcinoma
A phase II clinical trial demonstrated that combining avelumab and cetuximab nearly quadrupled median progression-free survival compared to avelumab alone in patients with advanced cutaneous squamous cell carcinoma.
Pimicotinib Achieves 54% Response Rate in Phase 3 Trial for Rare Joint Tumor
Pimicotinib demonstrated a statistically significant 54.0% objective response rate versus 3.2% for placebo in the global Phase 3 MANEUVER trial for tenosynovial giant cell tumor.
PhaseV Secures $50M Series A to Transform Clinical Trials with AI Platform
PhaseV has raised $50 million in Series A funding led by Accel and Insight Partners, bringing its total funding to $65 million to expand its AI-driven clinical development platform.
Walden Biosciences Strengthens Board with Appointment of Rare Disease Expert Howard Mayer
Walden Biosciences has appointed Howard Mayer, M.D., former Executive VP of R&D at Ipsen, to its Board of Directors as the company approaches key clinical milestones.
Bionxt Solutions to Evaluate Sublingual Cladribine Formulation for Multiple Sclerosis in Clinical Trial
Bionxt Solutions plans to initiate a clinical trial in the second half of 2025 to assess its sublingual cladribine formulation, BNT23001, for treating multiple sclerosis.
Patient-Centric Approaches and Technology Reshape Clinical Trial Landscape, Industry Experts Report
Only 39% of clinical trial sites achieve enrollment targets according to Tufts Center, highlighting critical recruitment challenges in drug development.